Treatment decisions for neovascular age-related macular degeneration (nAMD) in the setting of individualised treatment regimens are adapted to disease activity. The main marker of disease activity and trigger for re-treatment with anti-vascular endothelial growth factor (anti-VEGF) agents is the presence of retinal fluid on optical coherence tomography (OCT). Recently, attention has focused on the impact of residual retinal fluid on nAMD management. Based on a literature review and the combined clinical experience of an international group of retinal specialists, this manuscript provides expert guidance on the treatment of nAMD according to fluid status and proposes an algorithm for determining when to administer anti-VEGF treatment according to residual fluid status. We explore the role of residual fluid in treatment decisions and outcomes in nAMD, taking into consideration fluid evaluation and, in particular, distinguishing between fluid in different anatomic compartments and at different stages during the treatment course. Current limitations to identifying and interpreting fluid on OCT, and the assumption that any residual retinal fluid reflects ongoing VEGF activity, are discussed. No data are available.

中文翻译：

---

残余视网膜液对新生血管性年龄相关性黄斑变性治疗结果的影响


在个体化治疗方案中，新生血管性年龄相关性黄斑变性 (nAMD) 的治疗决策应根据疾病活动情况进行调整。疾病活动性和再次使用抗血管内皮生长因子（抗 VEGF）药物治疗的触发因素的主要标志是光学相干断层扫描（OCT）上存在视网膜液体。最近，人们的注意力集中在残留视网膜液对 nAMD 治疗的影响上。基于文献综述和国际视网膜专家组的综合临床经验，本文为根据液体状态治疗 nAMD 提供了专家指导，并提出了一种根据残留液体状态确定何时进行抗 VEGF 治疗的算法。我们探讨了残留液体在 nAMD 治疗决策和结果中的作用，考虑到液体评估，特别是区分治疗过程中不同解剖部位和不同阶段的液体。讨论了目前 OCT 上识别和解释液体的局限性，以及任何残留的视网膜液体反映持续的 VEGF 活性的假设。无可用数据。